Variabilität des Therapieansprechens von Gemcitabin bei Pankreaskarzinom: Identifizierung relevanter Genpolymorphismen
Retrospektive Studie bei Patienten mit Pankreaskarzinom
Variability of therapy response in gemcitabine treated pancreatic carcinoma: Identifying relevant gene polymorphisms
Retrospectiv study in patients with pancreatic carcinoma
by Alexander Schaudinn
Date of Examination:2013-01-28
Date of issue:2013-01-23
Advisor:Prof. Dr. Jürgen Brockmöller
Referee:Prof. Dr. Jürgen Brockmöller
Referee:PD Dr. Torsten Liersch
Files in this item
Name:Dissertation A.Schaudinn 21.01.2013 Final.pdf
Size:2.90Mb
Format:PDF
Description:Dissertation PDF
Name:Dissertation A.Schaudinn 21.01.2013 Final.docx
Size:3.11Mb
Format:VND.OPENXMLFORMATS-OFFICEDOCUMENT.WORDPROCESSINGML.DOCUMENT
Description:Dissertation WORD
Abstract
English
Gene polymophisms could play an important role in the variability of therapy response in gemcitabine treated patients with pancreatic carcinoma. The retrospective study showed that a polymorphism in ENT-1, a carrier of gemcitabine, had an influence on overall survival.
Keywords: Gemcitabine; Gene Polymorphism; ENT1; Pancreatic Carcinoma